CROP Hemp-CBD Farm Enters Toll Processing Deal to Produce CBD Isolate as it Readies for Harvest
Momentum Public Relations
Press Release: October 10, 2018
CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR)announced today that its tenant has signed a toll processing deal whereby it will provide its dried hemp-CBD biomass to a processor who will then provide 50% of the finished product as ISO certified CBD isolate to CROP’s tenanted farm. The CBD isolate will be sold under the company’s brands Hempire, Tiff CBD, infused in to the company’s CannaDrink and sold under white label.
CROP’s tenant, at its Nye County hemp-CBD farm in Nevada, has already begun equipment readiness preparations as the harvest is imminent.
CROP will also be working with the toll processor to enter into further agreements to develop its own ISO extraction facility for its production capacity which is now expanded to over 1,800 acres for 2019. The processor has consulted with numerous Canadian ACMPR and US licensed cannabis cultivators and processors to develop GMP and ISO conforming extraction facilities.
According to cannabis industry analysts, The Brightfield Group, it is estimated the hemp CBD market alone could hit $22-billion by 2022.
CROP CEO, Michael Yorke, stated: “Being in a position to have CBD isolate from the 2018 harvest will enable the company to begin infusing products like the CannaDrink beverage line and begin developing relationships with bulk buyers in preparation for 2019. Even with a toll cost, upgrading CBD biomass to isolate should significantly increase the value of our tenant harvest. This new strategic-alliance opens up additional mutually beneficial opportunities, specifically those in developing our own extraction facilities, both in the US and Europe, which will be necessary to maximize the potential of our portfolio’s ongoing hemp-CBD and Cannabis-THC production.”
About CROP
CROP has a portfolio of cannabis projects including cultivation properties in California, two in Washington State, two in Nevada consisting of 2,800 acres, 3 dispensary applications, with international focuses in Jamaica and 2 farms in Italy. CROP has developed a portfolio of assets including CannaDrink and a portfolio of 16 Cannabis brands. with US and Italian distribution rights to over 55 topical products.
Company Contact
Michael Yorke – CEO & Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (1) 604-484-4206
- Published in Business, CROP Infrastructure, Life Sciences, Medical Marijuana, News Home
CROP to Infuse its ‘CannaDrink’ Functional Beverage With Naturally Splendid’s HempOmega™
Momentum Public Relations
Press Release: October 3, 2018
CROP Infrastructure Corp. (CSE: CROP) (CSE: CROP.CN) (OTC: CRXPF)(Frankfurt: 2FR) (“CROP“ or the “Company“) announces that further to its LOI with Naturally Splendid Enterprises (TSX-V: NSP)(OTCQB: NSPDF) (previously announced on August 14th 2018) CROP will utilize NSP’s proprietary HempOmega™ powder created from microencapsulated hemp seed oil in its ‘CannaDrink’ functional beverage line currently being developed.
CannaDrink will now be available in all other jurisdictions containing HempOmega™ where CBD products are not yet approved. CROP’s new cannabis-infused line of soft drinks called CannaDrink will be a zero calorie, non-GMO, ketogenic-friendly line of soda pop, tea, and coffee variations.
HempOmega™ is a unique and proprietary homogenous powder created from microencapsulated hemp seed oil. It is a high-quality and sustainable omega fatty acid alternative ingredient. Due to its unique powder format, it solves the formulation challenge manufacturers face when trying to add oil to existing products and has proven to increase the bioavailability of omega fatty acids. The global carbonated soft drinks market is projected to reach USD 605.6 billion by 2025, according to a March 2018 report by Grand View Research, Inc.
In addition to its CannaDrink beverage line, CROP is working with Naturally Splendid to develop a “Hempire” branded hulled hemp seed and protein powder product line. CROP and Naturally Splendid are currently testing a variety of flavors and formulations created by NSP specifically for the Hempire Brand that will be enhanced with NSP’s HempOmega™.
Naturally Splendid CEO Mr. Douglas Mason states, “We are pleased to be working with CROP to create quality, white-labelled hemp products for the Hempire brand as well as providing our proprietary HempOmega™ ingredient for CROP’s innovative CannaDrink functional soft drink line. CannaDrink is formulated to deliver superior omega nutrition, by utilizing Naturally Splendid’s proprietary HempOmega™it provides ‘first mover advantage’ for Naturally Splendid and CROP to formulate cannabis formulated beverages and edibles as HempOmega™ has been approved for product fortification without the concern or restrictions of cannabinoid formulated beverages and edibles
Michael Yorke, CEO and Director of CROP Infrastructure states: “We believe in the nutritional spectrum and health benefits of both hemp and CBD so adding a consumer goods vertical was a logical progression as consumer data shows strong trends in plant-based foods and nutritional products. We see it as a tremendous opportunity for CROP Infrastructure’s branding & IP portfolio.”
About CROP
Crop has a portfolio of cannabis projects including cultivation properties in California, two in Washington State, two in Nevada consisting of 2,800 acres including extraction, 3 dispensary applications, with international focuses in Jamaica and Italy. CROP has developed a portfolio of assets including Canna Drink with US and Italian distribution rights to over 55 topical products and a portfolio of 16 Cannabis brands.
Disclaimer for Forward-Looking Information
Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding CannaDrink; the technological effects of CannaDrink; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Company Contact
Michael Yorke – CEO & Director
E-mail: info@cropcorp.com
Website: http://www.cropcorp.com
Phone: +1-604-484-4206
- Published in Business, CROP Infrastructure, Medical Marijuana, News Home
Tetra Bio-Pharma Moves PPP001 Closer to Commercial Manufacturing with the Issuance of a Drug Establishment License to Ford’s Pharmacy
Momentum Public Relations
Press Release: October 3, 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), in partnership with Ford’s Family Pharmacy and Wellness Center, have developed and implemented a pharmaceutical quality system for Canada’s first botanical-based prescription drug PPP001. The Good Manufacturing Practices, Regulatory Operations and Regions Branch, Health Canada completed the inspection of Ford’s manufacturing facility. A Drug Establishment License (DEL) was granted after having inspected and assessed the facility as being in compliance with the requirements of Divisions 2 to 4 of the Food and Drug Regulations thereby allowing Ford’s to conduct the fabrication, packaging and labeling of PPP001.
Dr. Guy Chamberland, M.Sc., Ph.D., Interim CEO and CSO of Tetra Bio-Pharma stated, “This is a significant accomplishment for Tetra and Ford’s. The manufacturing of a botanical drug is a complex operation and we have demonstrated to Health Canada that we are able to manufacture PPP001 in compliance with the requirements for a prescription drug. The DEL was required not just to manufacture the commercial lots but simply to enable Tetra to apply for approval and obtain the Drug Identification Number (DIN). Tetra is now in an excellent position to focus its activities on scale-up to ensure that we can supply the market demand for a first cannabis botanical drug. The DEL, a recognition of the pharmaceutical GMP quality process by Health Canada, was a critical milestone for Tetra to achieve thereby allowing the corporation to accelerate its plans to register cannabis drugs around the world including Europe and the USA.”
Dr. Peter Ford, CEO of Ford’s Family Pharmacy and Wellness Centre stated, “This has been a true team effort between Tetra and Ford’s and will potentially represent the very first smokable dosage form in Canada and beyond. We are both very much committed to the DIN application.”
Ofer Yifrach-Stav, Tetra Bio-Pharma Vice President, Pharmaceutical Compliance and Quality, said, “Tetra is proud to present a significant milestone in the development of PPP001, a prescription drug that contains a botanical ingredient, manufactured under the stringent requirements and regulations of Health Canada. The GMP inspection addressed a wide range of production activities, and the results demonstrate our consistent adherence to establish procedures at every step of the production process, as well as our ability to provide a high-quality, clean, safe and reliable product. We are excited to take the next steps in the development of cannabis botanical drugs with the potential of making them widely available to the public.”
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
About Ford’s Family Pharmacy and Wellness Centre
Since 1997, Ford’s Family Pharmacy & Wellness Centre has helped clients improve and prolong their health, wellness and vitality by providing personalized compounding and wellness solutions. Our team, which currently consists of four pharmacists: Peter Ford, Bryan Sinclair, Candy Aguinaga, and Taylor White, 14 pharmacy technicians/assistants and two registered nurses, is attentive, compassionate, courteous and responsive. We pride ourselves on providing innovative solutions to complex medical problems, and work with Canadian healthcare providers (including physicians, veterinarians and dentists) to create well-rounded, comprehensive natural and compounding treatment plans. Our consultative approach, state-of-the-art technology and unique “Functional Medicine” position means we will work with you one-on-one to understand the root cause of your pain or other health issues and apply all our resources to developing the treatment that is right for you.
For more information visit: www.fordrx.com
Source: Tetra Bio-Pharma
- Published in Business, Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Crop Announces Major Expansion in Italy
Momentum Public Relations
Press Release: October 1, 2018
CROP INFRASTRUCTRE CORP. (CSE: CROP) (OTC: CRXPF)(Frankfurt: 2FR) announced today that it has leased a 87,120 square foot greenhouse facility in Italy through its joint venture with XHemplar. Work has already begun on upgrading the site security which includes cameras and fencing.
In addition, CROP will be working with XHemplar to open two retail locations before the end of the year, as well as build a state-of-the-art extraction facility.
CROP Infrastructure CEO, Michael Yorke, stated: “This will allow for low-cost and high-quality pure CBD isolate and CBD products to be sold domestically as well as into the European CBD market. The joint venture’s CBD products will be branded under the XHemplar and CROP brands Tiffany CBD and Hempire Italia.
“This is a major increase in our European footprint. Not only will this expand our growing capacity and quality control, but, very importantly, the build-out of an extraction facility will allow CROP to provide European markets with quality CBD isolate.”
According to cannabis industry analysts the Brightfield Group, it is estimated the hemp-CBD market alone could hit $22 billion by 2022.
About CROP
Crop Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, a 1,865 acre CBD farm, extraction in Nevada with international focuses in Jamaica and Italy and a joint venture on West Hollywood and San Bernardino dispensary applications.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
Company Contact
Michael Yorke – CEO & Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (1) 604-484-4206
- Published in Business, CROP Infrastructure, Medical Marijuana, News Home
North Bud Farms Announces Licensing of Cannabinoid Infusion Technology for Food and Beverage Platform
Momentum Public Relations
Press Release: September 27, 2018
North Bud Farms Inc.(CSE: NBUD) (“NORTHBUD” or the “Company”) is pleased to announce the licensing of infusion technology for its food and beverage platform with Made By Science Inc., a wholly owned subsidiary of Form Factory Inc.
The Company signed a supply and licensing agreement with Made By Science Inc. (“MBS”), an Oregon, California multi state co-packaging and infused product manufacturer. MBS owns a variety of IP protected infusion, encapsulation, taste masking and manufacturing processes.
This Agreement provides that NORTHBUD will purchase from MBS raw, non-infused protein-based encapsulation powder (MX-17) to be used for infusion and formulation purposes in the Canadian market. NORTHBUD and MBS have established a per gram cost as well as a royalty agreement where NORTHBUD will pay a floating royalty on business to business sales and a consumer direct sale.
The companies intend to negotiate a master licensing agreement (“the Agreement”) to include the licensing and use of multiple proprietary food infusion technologies for which MBS will grant a master license for NORTHBUD to the use of the patented technology.
“Over the past 8 months our team has researched many technology solutions pertaining to encapsulation and infusion of cannabinoids into foods and beverages,” said Ryan Brown, Founder and CEO of North Bud Farms Inc. “This agreement secures us access to a premier technology partner allowing us to leverage a proven technology and tested processes from an advanced consumer market. We believe this will accelerate NORTHBUD’s goal of developing a food grade cannabinoid infused taste neutral ingredient as a first step towards creating products that will follow in compliance with the upcoming regulations regarding infused consumables. Over the coming months we look forward to working with both Food and Cannabis industry participants as we establish our development platform in preparation for the legalization of edibles and consumables which is anticipated in October 2019.”
“Made By Science has been relentlessly innovating the science driving the infused edibles industry to provide brands and consumers with safe, efficient and accurate products. As our team continues to position as a best in class manufacturer in the U.S., we have had our sights set on Canada as both critical to our long-term expansion and essential for our ability to export to international markets. NORTHBUD was an early believer in our technology and our team and we are excited to support their efforts with innovation and scale,” said Joshua Held, President of Form Factory Inc.
In accordance with the corporate stock option plan, North Bud Farms has issued 85,000 options at a strike price of $0.60 to advisors and consultants assisting with this project. These options will vest over a 24-month period.
About Made By Science Inc.
Made By Science Inc. is a wholly owned subsidiary of Form Factory Inc., a multi state manufacturer of cannabis infused food and beverage products.
For more information visit: www.madebyscience.co
About North Bud Farms Inc.
North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR). North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.
For more information visit: www.northbud.com
- Published in Business, Medical Marijuana, News Home, NorthBud
AREV Shifts into High Gear — CFN Media
Momentum Public Relations
In The News: September 26, 2018
AREV Brands International (CSE: AREV) is a cannabis integrator that has parlayed its history with natural health products into an intriguing and streamlined cannabis company. Through a series of accretive acquisitions, the company has transformed into a Canadian-based cannabis operator with international ambitions.
Genetics, the Foundation of Quality and Consistency
AREV recently acquired BC Bud Depot, one of the world’s most respected and awarded breeders and marketers that features an internationally recognized brand and an extensive seed bank of hundreds of strains. Starting with 2004’s win at the High Times Cannabis Cup, the first win for a Canadian company in international competition, BC Bud Depot strains have up more than 40 awards from cannabis competitions.
Genetics and proprietary strains are important for both the medical and adult-use markets. In the medical arena, consistent and specific genetic traits produce consistent and specific terpene and cannabinoid profiles, thereby providing a remedy for a targeted area of health such as Anxiety, Central Nervous System, Insomnia, Libido and Pain Management. AREV has taken an in-depth look at the BCBD seed bank and identified several strains that deliver a specific experience to the consumer. Due to intelligent strain selection and processing, consumers can choose how they would like to feel. They can Relax, be Energized, Create, all based on easy to understand labelling.
AREV sees both wholesale and retail potential from its seed bank. The strains could be sold outright to licensed producers, or they could be the foundation of a partnership where the LP cultivates the plant and sells it back to AREV for distribution. The cultivation risk and expense is off-loaded to the growers and AREV controls the genetics. The opportunity is not limited to North America, as the company has incorporated in Ireland and Germany to build on its international infrastructure.
The BC Bud Depot acquisition also netted a couple of other key assets. One, the company has an extensive database of over 50,000 customers and potential customers, a list that is invaluable as AREV grows its business both with cultivators and in other aspects of the industry. Two, BC Bud Depot has 10 years of pre-paid advertising on the prime inside front cover of High Times magazine.
Extraction and Innovation
AREV controls 28 acres in the Southern Interior of British Columbia. It plans to leverage an ACMPR license to develop a breeding, nursery, laboratory, and extraction facility that will further expand the company’s capabilities in relation not only to cannabis but to the development of other medicinal plant-based products.
AREV cut its teeth on plant-based, scientifically derived products utilizing extracts from a variety of medicinal plants. In a joint venture with a related company, Alternative Extracts Inc., the company utilizes state of the art extraction techniques to create pure and consistent concentrates that form the foundation for nutritional and nutraceutical products. AREV recently announced that this joint venture has perfected the infusion of oil-based extracts (like the cannabinoids and terpenes from cannabis) into beverages, including beer, wine, ciders, and fruit juices. The proprietary extraction method preserves the natural characteristics of the active ingredients, including flavor.
By adjusting the terpene profiles, AREV’s CBD and THC based products can now deliver a specific experience to the consumer. This enables the company to profile the experience the consumer has while enjoying products with AREV’s ingredients. With the cannabis industry headed more toward extract-based products, both medicinally and recreationally, and away from smoked cannabis flower, a breakthrough like this could be transformative for the company. Beverages are in their infancy, and technology that can deliver all of the desirable characteristics from the flower in beverage form would certainly bring change to the beverage industry. AREV’s terpene profiling is not limited to the cannabis industry. It can be used in many food and beverage products currently sold in unregulated markets.
Products and Distribution
AREV’s COCO-MULSION products are sold in the health and wellness sector. These products come in formulations that support relaxation, brain function, and physical performance. They are Health Canada certified and distributed throughout the country. The company also has Canadian distribution rights to the Bare Topicals line of cannabis-based creams intended for pain relief and treatment of skin conditions. In the pipeline, AREV intends to launch a line of CBD sport nutrition supplements along with a CANNA-MULSION CBD with its new brand ambassador Patrick Cote, former UFC Champion. The company has also collaborated with Alternative Extracts to come up with a THC delivery system and a full line of cannabis oils and sprays.
Some of these products need the proper ACMPR licenses for distribution, while others can be offered over the counter as they derive from hemp rather than cannabis. Either way, the fact that AREV has lines of distribution in place and products currently in the market bodes well for the successful introduction of new products in the future.
Please follow the link to read the full article: http://www.cannabisfn.com/arev-shifts-high-gear/
Disclaimer
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
- Published in AREV Nutrition Sciences, Business, Medical Marijuana, News Home
Sirona Biochem Receives Positive Safety Data for Lead Skin-Lightener in Preparation for Clinical Trial in the US
Momentum Public Relations
Press Release: September 26, 2018
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (Xetra: ZSB) (the “Company”) is pleased to report further progress regarding the clinical development of its lead skin-lightener, TFC-1067.
In parallel with ongoing partnering discussions, Sirona has completed steps toward the clinical trial for TFC-1067. A toxicologist, from CEHTRA in Paris, was hired to approve Sirona’s compound for clinical use. From the pre-clinical data, the toxicologist established a clinical dose for the compound and further confirmed that it does not degrade into toxic metabolites such as hydroquinone and benzoquinone.
The Company also contracted formulation expert Gael Boutry of Global Beauty Consulting in France to develop a formulation acceptable for clinical use. The formulation (face cream) containing TFC-1067 has already been prepared, packaged and tested in an accelerated stability test to ensure shelf-life.
Over the past two months, safety studies with the formulation have been ongoing at Dermscan, Poland, and continue to provide positive data for TFC-1067. The first study, a human patch test on 10 people, confirmed TFC-1067 as a non-irritant, in contrast to many other skin-lighteners.
In early August, a second clinical trial for the Human Repeat Insult Patch Test (HRIPT) which assesses sensitization on a larger group (110 people) began, in preparation for future efficacy trials. Initial results from the panel show TFC-1067 as a non-sensitizer. With these tests completed, Sirona will begin their proof of efficacy clinical trial in October, at a center in the United States, led by an acclaimed dermatologist.
“The significance of the data that supports the formulated TFC-1067 cream as a non-irritant, non-sensitizer cannot be understated, as many common skin-lighteners, like hydroquinone, resorcinol, and Kojic Acid, have known toxicities at effective doses,” said Dr. Howard Verrico, CEO of Sirona Biochem. “The market has an unmet need with the safety and efficacy problems associated with the currently available skin lighteners and we are confident that TFC-1067 will meet this need. With an inventory of formulated product, we are primed to start the trial in October.”
The planned clinical trial does not prevent negotiations of a definitive agreement in the interim. Advancing the development continues to add value to TFC-1067 and shorten the time to full commercialization. This improves our future potential partners ability to share our confidence in the commercial opportunity we are creating. In parallel, meetings with North American and Asian cosmetic companies continue to move forward.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Business, Life Sciences, News Home, Sirona Biochem